News from wuxi biologics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Aug 19, 2019, 10:09 ET WuXi Biologics Reports Outstanding Interim Results

52.4% Year-on-Year Revenue Growth to RMB1,607.1 Million Net Profit Increased 80.1% Year-on-Year to RMB449.5 Million Gross Profit Margin, Net Profit...


Jun 20, 2019, 20:22 ET WuXi Biologics to Expand Integrated Biologics Conjugation Solution Center to Include Commercial Manufacturing

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics ...


Jun 04, 2019, 21:05 ET WuXi Biologics Hosts Successful Inaugural Investor Day

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics ...


May 20, 2019, 19:28 ET WuXi Biologics Signed Letter of Intent for Long-Term Vaccine Manufacturing Contract

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics ...


May 16, 2019, 03:28 ET WuXi Biologics Commenced Construction of a 48,000 L Integrated Manufacturing Center for Innovative Biologics in Chengdu

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics ...


Apr 16, 2019, 21:00 ET WuXi Biologics Successfully Completed First FDA Routine GMP Inspection

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics ...


Apr 16, 2019, 07:53 ET WuXi Biologics and I-Mab Biopharma Announce Long-term Strategic Manufacturing Partnership for Five Clinical and One Commercial Programs

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics ...


Apr 08, 2019, 20:25 ET WuXi Biologics and NBE-Therapeutics Announce Comprehensive ADC Development and Manufacturing Partnership

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics ...


Apr 03, 2019, 08:01 ET WuXi Biologics Wins 2019 CMO Leadership Awards in All Six Core Categories

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics ...


Mar 25, 2019, 20:21 ET WuXi Biologics Receives "Asia's Best CMO of 2018" Award from IMAPAC

WuXi Biologics ("WuXi Bio") (Stock Code: 2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions...


Mar 19, 2019, 20:07 ET WuXi Biologics Receives EMA GMP Certificates

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics ...


Mar 18, 2019, 10:21 ET WuXi Biologics Continues to Deliver Record Results

WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global open-access biologics technology platform...


Feb 27, 2019, 20:33 ET WuXi Biologics Congratulates Amicus on Receiving FDA Breakthrough Therapy Designation for AT-GAA

WuXi Biologics ("WuXi Bio") (Stock code: 2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions...


Feb 25, 2019, 19:20 ET ABL Bio Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody(TM) Platform for Novel Immune Check Point Bispecifics for $220 Million

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics ...


Feb 18, 2019, 19:21 ET EMA Completed Pre-Approval Inspection of cGMP DS and DP Facilities for Trogarzo(TM) at WuXi Biologics

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics ...


Feb 11, 2019, 19:00 ET WuXi Biologics and Amicus Sign Exclusive Manufacturing Partnership

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics ...


Dec 19, 2018, 07:13 ET WuXi Biologics and AC Immune to Establish an Exclusive Strategic Partnership

WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company that offers end-to-end solutions for biologics...


Dec 12, 2018, 18:30 ET WuXi Biologics Congratulates Tychan on First-in-Class Monoclonal Antibody for Yellow Fever after Record 7 Months of Development

WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company that offers end-to-end solutions for biologics...


Dec 11, 2018, 18:51 ET WuXi Biologics Achieves Breakthrough Titer of 51g/L in Cell Culture Productivity

WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery,...


Dec 10, 2018, 20:47 ET Oxford BioTherapeutics Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Five Bispecific Antibody Programs for up to $450 Million

WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery,...


Dec 09, 2018, 21:21 ET WuXi Biologics Announced Exclusive Discovery Research with Brii Biosciences for Novel Bispecific Antibody Immunotherapeutics

WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery,...


Dec 06, 2018, 05:12 ET WuXi Biologics Wins SCRIP Award for "Best Company in an Emerging Market"

WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company that offers end-to-end solutions for biologics...


Dec 05, 2018, 09:54 ET WuXi Biologics Commenced Construction of the Largest Biomanufacturing Facility Using Single-Use Bioreactors in Ireland

WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery,...


Nov 29, 2018, 08:22 ET WuXi Biologics Selected as Forbes Asia's Best Under A Billion 2018

WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery,...


Nov 28, 2018, 06:44 ET WuXi Biologics and ABL Bio Enter an Exclusive Development and Clinical Manufacturing Partnership for Multiple Bispecific Antibodies

WuXi Biologics (2269.HK, WuXi Bio), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics...